Across TCGA pan-cancer cohorts, GTF2E2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GTF2E2 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher GTF2E2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GTF2E2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUSC, KICH, and SKCM are the cancer types where GTF2E2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.168	0.675	.021	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SKCM	DFS	Median	All	0.808	0.199	.016	7	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: GTF2E2 tumor-vs-normal RNA expression · all GTF2E2 data types